Sandoz says Enbrel biosimilar equivalent in psoriasis study

In the Phase III EGALITY study, the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said its GP2015 met the primary endpoint of demonstrating equivalent efficacy to reference product Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN) based on PASI 75 response rates at week 12.

The study enrolled 531 patients with moderate to severe chronic plaque psoriasis. Data were presented at the Psoriasis International Network meeting in Paris. ...